Literature DB >> 24302647

MYB immunostaining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine-needle aspiration biopsy specimens.

Marc P Pusztaszeri1, Peter M Sadow, Aya Ushiku, Patrizia Bordignon, Thomas A McKee, William C Faquin.   

Abstract

BACKGROUND: The distinction between adenoid cystic carcinoma (ACC) and pleomorphic adenoma (PA) on fine-needle aspiration biopsy (FNAB) can be challenging. Recently, a specific translocation t(6;9) involving the v-myb avian myeloblastosis viral oncogene homolog (MYB) and nuclear factor I/B (NFIB) genes was identified in ACCs, in which it contributes to MYB overexpression. The authors investigated the use of MYB immunocytochemistry in FNAB specimens as an ancillary test for the cytologic diagnosis of ACC.
METHODS: The expression of MYB was assessed in alcohol-fixed cytologic smears of histologically confirmed ACCs (n = 20) and PAs (n = 20) using immunocytochemistry. The corresponding ACCs and PAs from formalin-fixed, paraffin embedded surgical resection specimens also were stained immunohistochemically for MYB. The nuclear expression of MYB was assessed semiquantitatively using a scoring system (from 0 to 6) that combined the proportion and the intensity of staining. A score ≥4 was considered positive, and a score ≤3 was considered negative.
RESULTS: On FNAB material, 80% of ACCs (N = 16 of 20) were immunocytochemically positive for MYB. In contrast, all PAs (N = 20 of 20) were negative for MYB (P < .0001). The sensitivity of MYB on FNAB was 80%, and the specificity was 100% relative to PA. Results on corresponding histology were similar to the cytology results; however, there was often a zonal staining pattern with central areas of tumor (range, 20%-90%) that lacked immunoreactivity, thus suggesting that the immunoreactivity was maintained better in alcohol-fixed FNAB material.
CONCLUSIONS: In contrast to PAs, a majority of ACCs are immunocytochemically positive for MYB. The test is more effective using alcohol-fixed FNAB material and is potentially useful for the cytologic distinction of ACC and PA.
© 2013 American Cancer Society.

Entities:  

Keywords:  MYB; adenoid cystic carcinoma; biopsy; fine-needle aspiration; immunochemistry; pleomorphic adenoma

Mesh:

Year:  2013        PMID: 24302647     DOI: 10.1002/cncy.21381

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  7 in total

1.  Fusion proteins in head and neck neoplasms: Clinical implications, genetics, and future directions for targeting.

Authors:  Derek A Escalante; He Wang; Christopher E Fundakowski
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

2.  Analysis of clinicopathological characteristics, MYB rearrangement and prognostic factors in salivary adenoid cystic carcinoma.

Authors:  Jing Han; Chunye Zhang; Ting Gu; Xi Yang; Longwei Hu; Zhen Tian; Jiang Li; Chenping Zhang
Journal:  Oncol Lett       Date:  2019-01-15       Impact factor: 2.967

3.  Cytology of Primary Salivary Gland-Type Tumors of the Lower Respiratory Tract: Report of 15 Cases and Review of the Literature.

Authors:  Chiara Saglietti; Marco Volante; Stefano La Rosa; Igor Letovanec; Marc Pusztaszeri; Gaia Gatti; Massimo Bongiovanni
Journal:  Front Med (Lausanne)       Date:  2017-04-24

Review 4.  Adenoid cystic carcinoma: emerging role of translocations and gene fusions.

Authors:  Piotr T Wysocki; Evgeny Izumchenko; Juliet Meir; Patrick K Ha; David Sidransky; Mariana Brait
Journal:  Oncotarget       Date:  2016-10-04

5.  Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.

Authors:  Julia Thierauf; Nisha Ramamurthy; Vickie Y Jo; Hayley Robinson; Ryan P Frazier; Jonathan Gonzalez; Maciej Pacula; Enrique Dominguez Meneses; Vania Nose; Valentina Nardi; Dora Dias-Santagata; Long P Le; Derrick T Lin; William C Faquin; Lori J Wirth; Jochen Hess; A John Iafrate; Jochen K Lennerz
Journal:  Oncologist       Date:  2019-03-29

6.  Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes.

Authors:  Candace A Frerich; Kathryn J Brayer; Brandon M Painter; Huining Kang; Yoshitsugu Mitani; Adel K El-Naggar; Scott A Ness
Journal:  Oncotarget       Date:  2017-12-23

Review 7.  Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.

Authors:  Patrick M Dillon; Samhita Chakraborty; Christopher A Moskaluk; Prashant J Joshi; Christopher Y Thomas
Journal:  Head Neck       Date:  2015-06-16       Impact factor: 3.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.